person · Reporting owner

GOLDSMITH MARK A

Disclosed activity across 2 companies

Tapewire entity: 19850
SEC CIK: 0001246842

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Revolution Medicines, Inc.RVMD · Entity 606	Director · See Remarks	September 16, 2026	September 18, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Revolution Medicines, Inc.

Report date September 16, 2026 · Filed September 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	267,117	Reported balance After 2026-09-16 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-09-16 · Sale · Disposed 213 · Balance 267,117 F1: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units. F2: The transaction was executed in multiple trades at prices ranging from $195.00 to $195.03, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Common StockSEC Table I · non-derivative	Direct	253,342	Reported balance After 2026-09-16 transaction · row 2 Account or security details depend on footnotes; rows are not merged. 1 source row Row 2 · 2026-09-16 · Sale · Disposed 13,775 · Balance 253,342 F1: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units. F3: Includes 157,588 restricted stock units.
Common StockSEC Table I · non-derivative	IndirectTrust	594,060	Reported balance Holding disclosure · report date 2026-09-16 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 594,060 F4: Held by Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust.
Common StockSEC Table I · non-derivative	IndirectTrust	61,424	Reported balance Holding disclosure · report date 2026-09-16 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 61,424 F5: Held by Jonathan Goldsmith Revocable Trust.
Common StockSEC Table I · non-derivative	IndirectTrust	61,424	Reported balance Holding disclosure · report date 2026-09-16 · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · Balance 61,424 F6: Held by Rebecca Goldsmith Revocable Trust.

Filing footnotes · ownership attribution and instrument terms

F1: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units.

F2: The transaction was executed in multiple trades at prices ranging from $195.00 to $195.03, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F3: Includes 157,588 restricted stock units.

F4: Held by Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust.

F5: Held by Jonathan Goldsmith Revocable Trust.

F6: Held by Rebecca Goldsmith Revocable Trust.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

CONSTELLATION PHARMACEUTICALS INC

Report date July 15, 2021 · Filed July 19, 2021

Section 16 reporting ended · disclosed 2021-07-19. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2021-07-15 transaction · row 1 1 source row Row 1 · 2021-07-15 · Disposition to issuer · Disposed 89,857 · Balance 0 F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the "Agreement"), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.57	Direct	Reported balance After 2021-07-15 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-07-15 · Disposition to issuer · Disposed 13,171 · Balance 0 F2: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.50	Direct	Reported balance After 2021-07-15 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-07-15 · Disposition to issuer · Disposed 6,825 · Balance 0 F2: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.12	Direct	Reported balance After 2021-07-15 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2021-07-15 · Disposition to issuer · Disposed 13,171 · Balance 0 F2: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.60	Direct	Reported balance After 2021-07-15 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2021-07-15 · Disposition to issuer · Disposed 12,446 · Balance 0 F2: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.51	Direct	Reported balance After 2021-07-15 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2021-07-15 · Disposition to issuer · Disposed 9,083 · Balance 0 F2: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.52	Direct	Reported balance After 2021-07-15 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2021-07-15 · Disposition to issuer · Disposed 13,171 · Balance 0 F2: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the "Agreement"), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").

F2: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
September 22, 2020 Filed Sep 24, 2020 00:36 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	541	$33.00	$17,853.00	Disclosure SEC source: 0001567619-20-017065 · doc1.xml · nonDerivative · entry 6 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Disclosed balance after: 101,879 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · ownership.nature: Held by the Goldsmith Children 2011 Irrevocable Education Trust. Read SEC document
September 22, 2020 Filed Sep 24, 2020 00:36 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	10,097	$33.15	$334,712.52	Disclosure SEC source: 0001567619-20-017065 · doc1.xml · nonDerivative · entry 5 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The transaction was executed in multiple trades in prices ranging from $33.00 to $33.39, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document
September 22, 2020 Filed Sep 24, 2020 00:36 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionCommon Stock	10,097	$4.09	$41,296.73	Disclosure SEC source: 0001567619-20-017065 · doc1.xml · nonDerivative · entry 4 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,097 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document
September 21, 2020 Filed Sep 24, 2020 00:36 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionStock Option (Right to Buy) · Derivative	29,903	$0.00 Strike: $4.09	$0.00	Disclosure SEC source: 0001567619-20-017065 · doc1.xml · derivative · entry 11 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 362,005 Underlying: Common Stock · 29,903 shares Expires 2029-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F6 · derivative.exercise_date: This option is early exercisable. One forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary measured from March 13, 2019 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document
September 21, 2020 Filed Sep 24, 2020 00:36 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	11,459	$33.00	$378,173.36	Disclosure SEC source: 0001567619-20-017065 · doc1.xml · nonDerivative · entry 3 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Disclosed balance after: 102,420 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $33.00 to $33.04, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · ownership.nature: Held by the Goldsmith Children 2011 Irrevocable Education Trust. Read SEC document
September 21, 2020 Filed Sep 24, 2020 00:36 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	29,903	$33.00	$986,849.84	Disclosure SEC source: 0001567619-20-017065 · doc1.xml · nonDerivative · entry 2 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $33.00 to $33.04, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document
September 21, 2020 Filed Sep 24, 2020 00:36 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionCommon Stock	29,903	$4.09	$122,303.27	Disclosure SEC source: 0001567619-20-017065 · doc1.xml · nonDerivative · entry 1 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,903 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document
September 18, 2020 Filed Sep 19, 2020 00:01 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionStock Option (Right to Buy) · Derivative	6,056	$0.00 Strike: $4.09	$0.00	Disclosure SEC source: 0001567619-20-016895 · doc1.xml · derivative · entry 16 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 391,908 Underlying: Common Stock · 6,056 shares Expires 2029-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F12 · derivative.exercise_date: This option is early exercisable. One forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary measured from March 13, 2019 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document
September 18, 2020 Filed Sep 19, 2020 00:01 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionStock Option (Right to Buy) · Derivative	1,286	$0.00 Strike: $1.12	$0.00	Disclosure SEC source: 0001567619-20-016895 · doc1.xml · derivative · entry 15 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,516 Underlying: Common Stock · 1,286 shares Expires 2028-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F11 · derivative.exercise_date: This option is early exercisable. One forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary measured from March 29, 2018 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document
September 18, 2020 Filed Sep 19, 2020 00:01 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	712	$31.05	$22,105.54	Disclosure SEC source: 0001567619-20-016895 · doc1.xml · nonDerivative · entry 11 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Disclosed balance after: 113,879 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F9 · price: The transaction was executed in multiple trades in prices ranging from $31.01 to $31.21, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F6 · ownership.nature: Held by the Goldsmith Children 2011 Irrevocable Education Trust. Read SEC document
September 18, 2020 Filed Sep 19, 2020 00:01 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	200	$32.19	$6,437.00	Disclosure SEC source: 0001567619-20-016895 · doc1.xml · nonDerivative · entry 10 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F8 · price: The transaction was executed in multiple trades in prices ranging from $32.13 to $32.24, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document
September 18, 2020 Filed Sep 19, 2020 00:01 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	7,142	$31.66	$226,083.58	Disclosure SEC source: 0001567619-20-016895 · doc1.xml · nonDerivative · entry 9 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F7 · price: The transaction was executed in multiple trades in prices ranging from $31.03 to $31.94, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document
September 18, 2020 Filed Sep 19, 2020 00:01 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionCommon Stock	6,056	$4.09	$24,769.04	Disclosure SEC source: 0001567619-20-016895 · doc1.xml · nonDerivative · entry 8 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,342 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document
September 18, 2020 Filed Sep 19, 2020 00:01 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionCommon Stock	1,286	$1.12	$1,440.32	Disclosure SEC source: 0001567619-20-016895 · doc1.xml · nonDerivative · entry 7 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,286 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document
September 17, 2020 Filed Sep 19, 2020 00:01 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionStock Option (Right to Buy) · Derivative	27,363	$0.00 Strike: $1.12	$0.00	Disclosure SEC source: 0001567619-20-016895 · doc1.xml · derivative · entry 14 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,802 Underlying: Common Stock · 27,363 shares Expires 2028-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F11 · derivative.exercise_date: This option is early exercisable. One forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary measured from March 29, 2018 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document
September 17, 2020 Filed Sep 19, 2020 00:01 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	11,288	$31.03	$350,310.66	Disclosure SEC source: 0001567619-20-016895 · doc1.xml · nonDerivative · entry 6 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Disclosed balance after: 114,591 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F5 · price: The transaction was executed in multiple trades in prices ranging from $31.00 to $31.15, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F6 · ownership.nature: Held by the Goldsmith Children 2011 Irrevocable Education Trust. Read SEC document
September 17, 2020 Filed Sep 19, 2020 00:01 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	22,658	$31.04	$703,191.03	Disclosure SEC source: 0001567619-20-016895 · doc1.xml · nonDerivative · entry 5 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The transaction was executed in multiple trades in prices ranging from $31.00 to $31.16, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document
September 17, 2020 Filed Sep 19, 2020 00:01 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	4,705	$29.76	$140,030.21	Disclosure SEC source: 0001567619-20-016895 · doc1.xml · nonDerivative · entry 4 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,658 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $29.09 to $29.98, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document
September 17, 2020 Filed Sep 19, 2020 00:01 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionCommon Stock	27,363	$1.12	$30,646.56	Disclosure SEC source: 0001567619-20-016895 · doc1.xml · nonDerivative · entry 3 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,363 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document
September 16, 2020 Filed Sep 19, 2020 00:01 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionStock Option (Right to Buy) · Derivative	8,813	$0.00 Strike: $1.12	$0.00	Disclosure SEC source: 0001567619-20-016895 · doc1.xml · derivative · entry 13 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,165 Underlying: Common Stock · 8,813 shares Expires 2028-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F11 · derivative.exercise_date: This option is early exercisable. One forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary measured from March 29, 2018 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document
September 16, 2020 Filed Sep 19, 2020 00:01 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	8,813	$29.04	$255,955.96	Disclosure SEC source: 0001567619-20-016895 · doc1.xml · nonDerivative · entry 2 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $29.00 to $29.24, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document
September 16, 2020 Filed Sep 19, 2020 00:01 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionCommon Stock	8,813	$1.12	$9,870.56	Disclosure SEC source: 0001567619-20-016895 · doc1.xml · nonDerivative · entry 1 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,813 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document
September 10, 2020 Filed Sep 11, 2020 22:35 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionStock Option (Right to Buy) · Derivative	2,544	$0.00 Strike: $1.12	$0.00	Disclosure SEC source: 0001567619-20-016647 · doc1.xml · derivative · entry 6 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,978 Underlying: Common Stock · 2,544 shares Expires 2028-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F7 · derivative.exercise_date: This option is early exercisable. One forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary measured from March 29, 2018 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document
September 10, 2020 Filed Sep 11, 2020 22:35 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	4,399	$29.00	$127,571.00	Disclosure SEC source: 0001567619-20-016647 · doc1.xml · nonDerivative · entry 4 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Disclosed balance after: 125,879 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F4 · balance_after: On September 9, 2020, Third Rock Ventures GP III, L.P. distributed 27 shares to the Goldsmith Children 2011 Irrevocable Education Trust through an in-kind, pro rata distribution without value. This distribution was exempt from Section 16 of the Exchange Act pursuant to Rule 16a-9. F2 · ownership.nature: Held by the Goldsmith Children 2011 Irrevocable Education Trust. Read SEC document
September 10, 2020 Filed Sep 11, 2020 22:35 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	2,544	$29.07	$73,947.72	Disclosure SEC source: 0001567619-20-016647 · doc1.xml · nonDerivative · entry 3 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $29.00 to $29.49, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document
September 10, 2020 Filed Sep 11, 2020 22:35 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionCommon Stock	2,544	$1.12	$2,849.28	Disclosure SEC source: 0001567619-20-016647 · doc1.xml · nonDerivative · entry 2 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,544 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document
September 09, 2020 Filed Sep 11, 2020 22:35 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	100	$29.00	$2,900.00	Disclosure SEC source: 0001567619-20-016647 · doc1.xml · nonDerivative · entry 1 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Disclosed balance after: 130,251 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · ownership.nature: Held by the Goldsmith Children 2011 Irrevocable Education Trust. Read SEC document
September 08, 2020 Filed Sep 11, 2020 01:31 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionStock Option (Right to Buy) · Derivative	900	$0.00 Strike: $1.12	$0.00	Disclosure SEC source: 0001567619-20-016620 · doc1.xml · derivative · entry 5 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,522 Underlying: Common Stock · 900 shares Expires 2028-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F5 · derivative.exercise_date: This option is early exercisable. One forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary measured from March 29, 2018 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document
September 08, 2020 Filed Sep 11, 2020 01:31 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	900	$29.05	$26,140.86	Disclosure SEC source: 0001567619-20-016620 · doc1.xml · nonDerivative · entry 3 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Disclosed balance after: 130,351 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $29.00 to $29.20, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · ownership.nature: Held by the Goldsmith Children 2011 Irrevocable Education Trust. Read SEC document
September 08, 2020 Filed Sep 11, 2020 01:31 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	900	$29.05	$26,145.00	Disclosure SEC source: 0001567619-20-016620 · doc1.xml · nonDerivative · entry 2 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $29.00 to $29.20, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document
September 08, 2020 Filed Sep 11, 2020 01:31 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionCommon Stock	900	$1.12	$1,008.00	Disclosure SEC source: 0001567619-20-016620 · doc1.xml · nonDerivative · entry 1 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document
September 03, 2020 Filed Sep 4, 2020 23:05 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionStock Option (Right to Buy) · Derivative	500	$0.00 Strike: $1.12	$0.00	Disclosure SEC source: 0001567619-20-016504 · doc1.xml · derivative · entry 9 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,422 Underlying: Common Stock · 500 shares Expires 2028-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F8 · derivative.exercise_date: This option is early exercisable. One forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary measured from March 29, 2018 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document
September 03, 2020 Filed Sep 4, 2020 23:05 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	700	$29.07	$20,352.01	Disclosure SEC source: 0001567619-20-016504 · doc1.xml · nonDerivative · entry 6 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Disclosed balance after: 131,251 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F6 · price: The transaction was executed in multiple trades in prices ranging from $29.03 to $29.10, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F4 · ownership.nature: Held by the Goldsmith Children 2011 Irrevocable Education Trust. Read SEC document
September 03, 2020 Filed Sep 4, 2020 23:05 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	500	$29.07	$14,533.00	Disclosure SEC source: 0001567619-20-016504 · doc1.xml · nonDerivative · entry 5 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F5 · price: The transaction was executed in multiple trades in prices ranging from $29.03 to $29.09, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document
September 03, 2020 Filed Sep 4, 2020 23:05 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionCommon Stock	500	$1.12	$560.00	Disclosure SEC source: 0001567619-20-016504 · doc1.xml · nonDerivative · entry 4 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document
September 02, 2020 Filed Sep 4, 2020 23:05 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionStock Option (Right to Buy) · Derivative	1,100	$0.00 Strike: $1.12	$0.00	Disclosure SEC source: 0001567619-20-016504 · doc1.xml · derivative · entry 8 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,922 Underlying: Common Stock · 1,100 shares Expires 2028-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F8 · derivative.exercise_date: This option is early exercisable. One forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary measured from March 29, 2018 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document
September 02, 2020 Filed Sep 4, 2020 23:05 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	800	$29.02	$23,212.96	Disclosure SEC source: 0001567619-20-016504 · doc1.xml · nonDerivative · entry 3 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Disclosed balance after: 131,951 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $29.00 to $29.04, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F4 · ownership.nature: Held by the Goldsmith Children 2011 Irrevocable Education Trust. Read SEC document
September 02, 2020 Filed Sep 4, 2020 23:05 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	1,100	$29.05	$31,959.95	Disclosure SEC source: 0001567619-20-016504 · doc1.xml · nonDerivative · entry 2 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $29.01 to $29.11, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document
September 02, 2020 Filed Sep 4, 2020 23:05 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionCommon Stock	1,100	$1.12	$1,232.00	Disclosure SEC source: 0001567619-20-016504 · doc1.xml · nonDerivative · entry 1 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document
August 27, 2020 Filed Aug 31, 2020 23:09 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionStock Option (Right to Buy) · Derivative	1,438	$0.00 Strike: $1.12	$0.00	Disclosure SEC source: 0001567619-20-016181 · doc1.xml · derivative · entry 5 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,022 Underlying: Common Stock · 1,438 shares Expires 2028-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F6 · derivative.exercise_date: This option is early exercisable. One forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary measured from March 29, 2018 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document
August 27, 2020 Filed Aug 31, 2020 23:09 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	1,101	$29.01	$31,939.02	Disclosure SEC source: 0001567619-20-016181 · doc1.xml · nonDerivative · entry 3 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Disclosed balance after: 132,751 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $29.00 to $29.03, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F4 · ownership.nature: Held by the Goldsmith Children 2011 Irrevocable Education Trust. Read SEC document
August 27, 2020 Filed Aug 31, 2020 23:09 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	1,438	$29.01	$41,713.36	Disclosure SEC source: 0001567619-20-016181 · doc1.xml · nonDerivative · entry 2 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $29.00 to $29.09, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document
August 27, 2020 Filed Aug 31, 2020 23:09 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionCommon Stock	1,438	$1.12	$1,610.56	Disclosure SEC source: 0001567619-20-016181 · doc1.xml · nonDerivative · entry 1 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,438 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document
August 13, 2020 Filed Aug 14, 2020 22:32 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionStock Option (Right to Buy) · Derivative	9,700	$0.00 Strike: $1.12	$0.00	Disclosure SEC source: 0001567619-20-015580 · doc1.xml · derivative · entry 17 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,460 Underlying: Common Stock · 9,700 shares Expires 2028-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F12 · derivative.exercise_date: This option is early exercisable. One forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary measured from March 29, 2018 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document
August 13, 2020 Filed Aug 14, 2020 22:32 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	3,900	$27.57	$107,521.83	Disclosure SEC source: 0001567619-20-015580 · doc1.xml · nonDerivative · entry 14 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Disclosed balance after: 133,852 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F9 · price: The transaction was executed in multiple trades in prices ranging from $27.1941 to $28.00, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F10 · ownership.nature: Held by the Goldsmith Children 2011 Irrevocable Education Trust. Read SEC document
August 13, 2020 Filed Aug 14, 2020 22:32 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	5,232	$28.28	$147,977.70	Disclosure SEC source: 0001567619-20-015580 · doc1.xml · nonDerivative · entry 13 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F8 · price: The transaction was executed in multiple trades in prices ranging from $28.00 to $28.75, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document
August 13, 2020 Filed Aug 14, 2020 22:32 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionCommon Stock	5,232	$1.12	$5,859.84	Disclosure SEC source: 0001567619-20-015580 · doc1.xml · nonDerivative · entry 12 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,232 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document
August 13, 2020 Filed Aug 14, 2020 22:32 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	4,468	$27.49	$122,808.79	Disclosure SEC source: 0001567619-20-015580 · doc1.xml · nonDerivative · entry 11 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F7 · price: The transaction was executed in multiple trades in prices ranging from $27.00 to $27.99, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document
August 13, 2020 Filed Aug 14, 2020 22:32 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionCommon Stock	4,468	$1.12	$5,004.16	Disclosure SEC source: 0001567619-20-015580 · doc1.xml · nonDerivative · entry 10 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,468 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document
August 12, 2020 Filed Aug 14, 2020 22:32 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionStock Option (Right to Buy) · Derivative	16,967	$0.00 Strike: $1.12	$0.00	Disclosure SEC source: 0001567619-20-015580 · doc1.xml · derivative · entry 16 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,160 Underlying: Common Stock · 16,967 shares Expires 2028-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F12 · derivative.exercise_date: This option is early exercisable. One forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary measured from March 29, 2018 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.